EU Pharmaceutical Manufacturer: Catherine Wilkes on Achieving HPAPI Manufacturing Success
Catherine Wilkes, Executive Director of Environmental, Health and Safety at Quotient Sciences featured in European Pharmaceutical Manufacturer explores how containment protocols shift when dealing with HPAPIs to meet the required safety standards.
Contract Pharma: Stephen McQuaker on HPAPI Manufacturing Trends
Contract Pharma's latest article on HPAPI manufacturing trends features Quotient Sciences' Director of Drug Development Consulting, Stephen McQuaker, who discusses the development of early-stage new chemical entity (NCE) drug candidates.
Evecxia Therapeutics and Quotient Sciences Complete Phase I Clinical Milestone for New Depression Treatment
A drug development partnership between Evecxia Therapeutics and Quotient Sciences has resulted in the successful delivery of a Phase 1 clinical testing program for Evecxia’s drug candidate EVX-101, which is in development for major depressive disorder (MDD).
BioPharm International: John McDermott on Drug Development Outsourcing
BioPharm International interviews our VP of Scientific Consulting, John McDermott, who discusses the latest trends in drug development outsourcing.
Quotient Sciences Presents at APS Basic Biopharmaceutics Workshop
Chris Roe, Principal Research Fellow, and Ricardo Diaz de Leon Ortega, Modelling and Simulation Research Fellow, attended and presented at the Basic Biopharmaceutics Workshop hosted by The Biopharmaceutics Focus Group of the Academy of Pharmaceutical Sciences UK in London.